Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinat... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Ad... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Com... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared w... Read More
U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794280) titled 'Antibacterial Effect and Soft Tissue Healing of Chlorhexidine-Coated Polyglactin 910 Suture... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared w... Read More
U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07795788) titled 'Correlation Between Artificial Intelligence-Based Fecal Coverage Area-Quantified Bowel Prep... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemothera... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccinatio... Read More
Singapore, Sept. 1 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients ... Read More